- Conditions
- Secondary Hyperparathyroidism, End Stage Renal Disease
- Interventions
- paricalcitol injection
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 6
- States / cities
- Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 217
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Interventions
- Plixorafenib
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Interventions
- Cinacalcet
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 28 Days to 2190 Days
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
- Conditions
- Hyperphosphatemia Related to Chronic Kidney Disease
- Interventions
- ferric citrate
- Drug
- Lead sponsor
- Keryx Biopharmaceuticals
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
- Conditions
- Acute Kidney Injury, Renal Injury, Kidney Disease
- Interventions
- AKI Risk Notification
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 28 Days to 21 Years
- Enrollment
- 12,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lupus Nephritis
- Interventions
- Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Pediatric Kidney Disease, Acute Kidney Injury
- Interventions
- HF20™
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Cincinnati, Ohio • Seattle, Washington
- Conditions
- Acute Kidney Injury, COVID
- Interventions
- Not listed
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- 7 Days to 25 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 29 more
- Conditions
- Spinal Cord Injuries, Neurogenic Bladder
- Interventions
- Locomotor Training
- Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
- Interventions
- voclosporin
- Drug
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
- Interventions
- Glutamine, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
- Interventions
- Genistein, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Acute Kidney Injury, Renal Replacement Therapy, Pediatric Intensive Care Unit
- Interventions
- Furosemide Stress Test Clinical Decision Support Tool
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Acute Kidney Injury
- Interventions
- Aminophylline, Placebo
- Drug
- Lead sponsor
- Le Bonheur Children's Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Urinary Tract Infections
- Interventions
- Bladder Stimulation technique
- Other
- Lead sponsor
- Children's Hospital of Michigan
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
- Interventions
- CHPP of Cisplatin, Abdominal Surgery
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Ivosidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
- Interventions
- Pazopanib (GW786034)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Jacksonville, Florida • Miami, Florida + 6 more
- Conditions
- Complicated Urinary Tract Infection, Pyelonephritis
- Interventions
- Ceftolozane/Tazobactam, Meropenem
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 7 Days to 17 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 6 more
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Aurora, Colorado
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more